reason report
outlook leav room upsid momentum build
pt
bottom line today market close report sale
y/i slightli ahead
pre-announc revenu januari beat estim
street estim time pre-announc
out-performance broad-bas intern
beat expect driven continu momentum new patient
add allow power on-going price headwind
increment posit vs pre-announc amount
ebit out-performance abl deliv oper
margin come estim
consensu us reinforces/
valid dxcm busi model make long-term oper
margin guidanc look conserv reiter
revenu guidanc indic growth
rate y/i provid conjunct
pre-announc us guidanc reinforc
belief well track exceed goal
-- reflect sale exist core
insulin-depend busi patient exclud
believ realist potenti increment revenu sourc
next year includ non-insulin use type patient in-
hospit gestat diabet -- compani need
deliv compound-annual-growth-rate reach long-term sale
target reason believ adopt momentum slow
notabl total sale growth acceler vs
bp guidanc us clearli reflect prudent
conservat manag like set bar low light
fairli unpredict move part price transit pharmaci
channel etc view long-term guidanc
conserv factor believ base-cas --
even borderlin bear-cas -- scenario new patient add
perspect leav ampl room upsid year
next year
reiter op rate pt pt --
previous -- appli ev/sal sale
share current trade ev sale
premium compar smid-cap med-tech compani
believ continu
deliv estim upsid sustain ev/sal multipl current level
ultim believ share warrant least modest premium
small-cap med-tech stock univers given massiv
highli under-penetrated total address market per
estim consist upsid potenti top-tier growth
medic suppli devic
sale
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
outlook higher sale
estim move higher y/i
y/i vs previous alreadi reflect
point price headwind increment point
rate inc share outperform price target
continu believ remain path consist beat rais time
come driven market seem pois potenti doubl next
year today dxcm market-lead posit continu build
momentum near medium term despit competit headwind anticip next-
gen launch reduc form factor improv ease-of-us
meaning lower cost us seem particularli well-posit best-in-class
statu fda industri work dilig toward ultim goal develop artifici
pancreasessenti cgm-augment insulin pump system automat accur
next month believ share trade appli ev/
sale sale share current trade ev
sale premium compar smid-cap med-tech compani
believ continu deliv estim upsid
sustain ev/sal multipl current level ultim believ share warrant
least modest premium small-cap med-tech stock univers given
massiv highli under-penetrated total address market per estim
consist upsid potenti top-tier growth outlook longer term
risk includ failur continu evolv sensor technolog includ verili product
type patient toward sensor-integr pump potenti price pressur
increas competit potenti product recal reimburs issu
dollar million except per share data
total good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
consensu division revenu item includ contributor visibl alpha
consensu estim
compani report svb leerink estim factset visibl alpha
dollar million except per share data
total good sold
research develop
revenu
consensu incom statement item includ contributor factset
consensu division revenu item includ contributor visibl alpha
consensu estim
compani report svb leerink estim factset visibl alpha
dollar million except per share data
good sold
product good sold
develop good sold
total good sold
research develop expens
sg sale
 sale
oper expens sale
compani report svb leerink estim
partner novo nordisk
partnership verili formerli googl life scienc
develop bandage-lik sensor togeth data analyt
address non-insulin-us type market sensor
label day
miniatur dispos bandage-lik sensor size
studi compar glycem qualiti life benefit
monitor cgm self-monitor blood glucos smbg
made studi particip primari care physician
decis base insight real-tim use
retrospect insight determin remot visit
studi assess patient type diabet
sub-optimal glycem control use multipl oral agent
abl make lifestyl chang result improv
glycem control use real-tim continu glucos
monitor rt-cgm target learn modul versu
trial complet
feb acceler effort verili expect complet
develop
time depend calibr
feb initi feasibl studi complet
 juli timelin affirm late earli launch
 februari expect limit launch late full launch
plan random patient
 januari complet enrol patient
prospect random multicent two-arm confirmatori studi plan enrol patient
 januari complet enrol patient
non-gaap oper margin
ebitda margin
non-gaap oper margin
ebitda margin
non-gaap oper margin
ebitda margin
oper margin ebitda margin
oper margin ebitda
margin
increas includ increment
spend on-intens
spend on-intens program
spend on-intens program
spend on-intens program
low-end
end
end
end
